 | • レポートコード：GIR-107A12023 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、急性呼吸窮迫症候群治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性呼吸窮迫症候群治療薬の種類別市場規模（メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他）、用途別市場規模（入院患者、外来患者）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・急性呼吸窮迫症候群治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Therabron Therapeutics, Inc.、Serendex Pharmaceuticals A/S、Silence Therapeutics Plc、Histocell S.L.、Altor BioScience Corporation、Athersys, Inc.、Faron Pharmaceuticals Oy、FirstString Research, Inc.、GlaxoSmithKline Plc、Phylogica Limited ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他 ・用途別分析2016年-2026年：入院患者、外来患者 ・急性呼吸窮迫症候群治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・急性呼吸窮迫症候群治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・急性呼吸窮迫症候群治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・急性呼吸窮迫症候群治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・急性呼吸窮迫症候群治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Acute Respiratory Distress Syndrome Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Acute Respiratory Distress Syndrome Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Acute Respiratory Distress Syndrome Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Acute Respiratory Distress Syndrome Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Methylprednisolone
Hydrocortisone
Calf Pulmonary Surfactant for Injection
Others
Market segment by Application, can be divided into
In-Patient
Out-Patient
Market segment by players, this report covers
Therabron Therapeutics, Inc.
Serendex Pharmaceuticals A/S
Silence Therapeutics Plc
Histocell S.L.
Altor BioScience Corporation
Athersys, Inc.
Faron Pharmaceuticals Oy
FirstString Research, Inc.
GlaxoSmithKline Plc
Phylogica Limited
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Acute Respiratory Distress Syndrome Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Acute Respiratory Distress Syndrome Therapeutics, with revenue, gross margin and global market share of Acute Respiratory Distress Syndrome Therapeutics from 2019 to 2021.
Chapter 3, the Acute Respiratory Distress Syndrome Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Acute Respiratory Distress Syndrome Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Acute Respiratory Distress Syndrome Therapeutics research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Acute Respiratory Distress Syndrome Therapeutics
1.2 Classification of Acute Respiratory Distress Syndrome Therapeutics by Type
1.2.1 Overview: Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Type in 2020
1.2.3 Methylprednisolone
1.2.4 Hydrocortisone
1.2.5 Calf Pulmonary Surfactant for Injection
1.2.6 Others
1.3 Global Acute Respiratory Distress Syndrome Therapeutics Market by Application
1.3.1 Overview: Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Global Acute Respiratory Distress Syndrome Therapeutics Market Size & Forecast
1.5 Global Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast by Region
1.5.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Acute Respiratory Distress Syndrome Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Acute Respiratory Distress Syndrome Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Respiratory Distress Syndrome Therapeutics Market Drivers
1.6.2 Acute Respiratory Distress Syndrome Therapeutics Market Restraints
1.6.3 Acute Respiratory Distress Syndrome Therapeutics Trends Analysis
2 Company Profiles
2.1 Therabron Therapeutics, Inc.
2.1.1 Therabron Therapeutics, Inc. Details
2.1.2 Therabron Therapeutics, Inc. Major Business
2.1.3 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.1.4 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Therabron Therapeutics, Inc. Recent Developments and Future Plans
2.2 Serendex Pharmaceuticals A/S
2.2.1 Serendex Pharmaceuticals A/S Details
2.2.2 Serendex Pharmaceuticals A/S Major Business
2.2.3 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.2.4 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Serendex Pharmaceuticals A/S Recent Developments and Future Plans
2.3 Silence Therapeutics Plc
2.3.1 Silence Therapeutics Plc Details
2.3.2 Silence Therapeutics Plc Major Business
2.3.3 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.3.4 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Silence Therapeutics Plc Recent Developments and Future Plans
2.4 Histocell S.L.
2.4.1 Histocell S.L. Details
2.4.2 Histocell S.L. Major Business
2.4.3 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.4.4 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Histocell S.L. Recent Developments and Future Plans
2.5 Altor BioScience Corporation
2.5.1 Altor BioScience Corporation Details
2.5.2 Altor BioScience Corporation Major Business
2.5.3 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.5.4 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Altor BioScience Corporation Recent Developments and Future Plans
2.6 Athersys, Inc.
2.6.1 Athersys, Inc. Details
2.6.2 Athersys, Inc. Major Business
2.6.3 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.6.4 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Athersys, Inc. Recent Developments and Future Plans
2.7 Faron Pharmaceuticals Oy
2.7.1 Faron Pharmaceuticals Oy Details
2.7.2 Faron Pharmaceuticals Oy Major Business
2.7.3 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.7.4 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Faron Pharmaceuticals Oy Recent Developments and Future Plans
2.8 FirstString Research, Inc.
2.8.1 FirstString Research, Inc. Details
2.8.2 FirstString Research, Inc. Major Business
2.8.3 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.8.4 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 FirstString Research, Inc. Recent Developments and Future Plans
2.9 GlaxoSmithKline Plc
2.9.1 GlaxoSmithKline Plc Details
2.9.2 GlaxoSmithKline Plc Major Business
2.9.3 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.9.4 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 GlaxoSmithKline Plc Recent Developments and Future Plans
2.10 Phylogica Limited
2.10.1 Phylogica Limited Details
2.10.2 Phylogica Limited Major Business
2.10.3 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
2.10.4 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Phylogica Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Acute Respiratory Distress Syndrome Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Acute Respiratory Distress Syndrome Therapeutics Players Market Share
3.2.2 Top 10 Acute Respiratory Distress Syndrome Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Acute Respiratory Distress Syndrome Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Acute Respiratory Distress Syndrome Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Acute Respiratory Distress Syndrome Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Acute Respiratory Distress Syndrome Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2026)
6.2 North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2026)
6.3 North America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
6.3.1 North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2026)
7.2 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2026)
7.3 Europe Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
7.3.1 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Market Size by Region
8.3.1 Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Region (2016-2026)
8.3.2 China Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2026)
9.2 South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2026)
9.3 South America Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
9.3.1 South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Market Size by Country
10.3.1 Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Acute Respiratory Distress Syndrome Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Acute Respiratory Distress Syndrome Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Therabron Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Therabron Therapeutics, Inc. Major Business
Table 8. Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 9. Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Serendex Pharmaceuticals A/S Corporate Information, Head Office, and Major Competitors
Table 11. Serendex Pharmaceuticals A/S Major Business
Table 12. Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 13. Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Silence Therapeutics Plc Corporate Information, Head Office, and Major Competitors
Table 15. Silence Therapeutics Plc Major Business
Table 16. Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 17. Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Histocell S.L. Corporate Information, Head Office, and Major Competitors
Table 19. Histocell S.L. Major Business
Table 20. Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 21. Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Altor BioScience Corporation Corporate Information, Head Office, and Major Competitors
Table 23. Altor BioScience Corporation Major Business
Table 24. Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 25. Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Athersys, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Athersys, Inc. Major Business
Table 28. Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 29. Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Faron Pharmaceuticals Oy Corporate Information, Head Office, and Major Competitors
Table 31. Faron Pharmaceuticals Oy Major Business
Table 32. Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 33. Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. FirstString Research, Inc. Corporate Information, Head Office, and Major Competitors
Table 35. FirstString Research, Inc. Major Business
Table 36. FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 37. FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. GlaxoSmithKline Plc Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline Plc Major Business
Table 40. GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 41. GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Phylogica Limited Corporate Information, Head Office, and Major Competitors
Table 43. Phylogica Limited Major Business
Table 44. Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Product and Solutions
Table 45. Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Acute Respiratory Distress Syndrome Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Acute Respiratory Distress Syndrome Therapeutics Players Head Office, Products and Services Provided
Table 50. Acute Respiratory Distress Syndrome Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Acute Respiratory Distress Syndrome Therapeutics New Entrants and Expansion Plans
Table 52. Global Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Type (2016-2021)
Table 54. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Forecast by Type (2021-2026)
Table 55. Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021)
Table 56. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Forecast by Application (2021-2026)
Table 57. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Acute Respiratory Distress Syndrome Therapeutics Picture
Figure 2. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Type in 2020
Figure 3. Methylprednisolone
Figure 4. Hydrocortisone
Figure 5. Calf Pulmonary Surfactant for Injection
Figure 6. Others
Figure 7. Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Application in 2020
Figure 8. In-Patient Picture
Figure 9. Out-Patient Picture
Figure 10. Global Acute Respiratory Distress Syndrome Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Acute Respiratory Distress Syndrome Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Acute Respiratory Distress Syndrome Therapeutics Market Drivers
Figure 20. Acute Respiratory Distress Syndrome Therapeutics Market Restraints
Figure 21. Acute Respiratory Distress Syndrome Therapeutics Market Trends
Figure 22. Therabron Therapeutics, Inc. Recent Developments and Future Plans
Figure 23. Serendex Pharmaceuticals A/S Recent Developments and Future Plans
Figure 24. Silence Therapeutics Plc Recent Developments and Future Plans
Figure 25. Histocell S.L. Recent Developments and Future Plans
Figure 26. Altor BioScience Corporation Recent Developments and Future Plans
Figure 27. Athersys, Inc. Recent Developments and Future Plans
Figure 28. Faron Pharmaceuticals Oy Recent Developments and Future Plans
Figure 29. FirstString Research, Inc. Recent Developments and Future Plans
Figure 30. GlaxoSmithKline Plc Recent Developments and Future Plans
Figure 31. Phylogica Limited Recent Developments and Future Plans
Figure 32. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Players in 2020
Figure 33. Acute Respiratory Distress Syndrome Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share in 2020
Figure 35. Global Top 10 Players Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Type in 2020
Figure 38. Global Acute Respiratory Distress Syndrome Therapeutics Market Share Forecast by Type (2021-2026)
Figure 39. Global Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Application in 2020
Figure 40. Global Acute Respiratory Distress Syndrome Therapeutics Market Share Forecast by Application (2021-2026)
Figure 41. North America Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Type (2016-2026)
Figure 42. North America Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Application (2016-2026)
Figure 43. North America Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Country (2016-2026)
Figure 44. United States Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Type (2016-2026)
Figure 48. Europe Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Application (2016-2026)
Figure 49. Europe Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Country (2016-2026)
Figure 50. Germany Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Region (2016-2026)
Figure 58. China Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Type (2016-2026)
Figure 65. South America Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Application (2016-2026)
Figure 66. South America Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Acute Respiratory Distress Syndrome Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の呼吸促迫症候群市場予測（～2024年）：企業別、地域別、種類・用途別 Description Scope of the Report: The global Respiratory Distress Syndrome market is valued at 360.1 million USD in 2018 and is expected to reach 442.6 million USD by the end of 2024, growing at a CAGR of 5.3% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following year…- 世界のレット症候群治療市場 2021：企業別、地域別、種類・用途別 The Rett Syndrome Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 急性腎不全用治療薬市場：世界及び中国市場分析・予測（～2024年） Acute Renal Failure Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Acute Renal Failure Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Acut…
- 急性リンパ性/リンパ芽球性白血病（ALL）治療薬の世界市場… Scope of the Report: The global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in fol…
- 世界のレノックス・ガストー症候群治療薬市場 2021：企業別、地域別、種類・用途別 The Lennox-Gastaut Syndrome Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade re…